We use cookies on our site to track usage and preferences. Learn more

Owlstone Medical Ltd

Life Sciences

Developing a breathalyzer for disease - with a focus on non-invasive diagnostics for cancer, inflammatory disease and infectious disease, the company aims to save 100,000 lives and $1.5B in healthcare costs.

  • Sector Life Sciences
  • Moved in 2015
  • Staff 180

Owlstone Medical’s mission is to save 100,000 lives and $1.5 billion in healthcare costs by developing Breath Biopsy® for applications in early detection and precision medicine across a wide range of diseases. Breath Biopsy detects biomarkers on breath such as volatile organic compounds (VOCs) and respiratory droplets.

VOC biomarkers originate from within the body as a result of metabolic and disease processes as from external sources including diet, environmental exposures and the microbiome. They are carried in the blood and exchange into breath in the lungs. Respiratory droplets arise in the lungs and are a medium for respiratory disease transmission as well as a source of macromolecular and non-volatile biomarkers.

Owlstone Medical is establishing a new diagnostic modality in breath with distinct advantages over existing approaches. The company offers an end-to-end platform for sample collection and analysis to support clinicians, academics and pharmaceutical researchers. Their Breath Biopsy Collection station, including ReCIVA® Breath Sampler enables non-invasive sampling with background reduction and pre-concentration to maximize sensitivity. Owlstone Medical provides comprehensive sample analysis services through the Breath Biopsy OMNI Assay that delivers high quality biomarker discovery, identification and validation using Thermo Fisher™ GC-Orbitrap™ technologies. You can also target specific processes for precision analysis with EVOC® Probes; using administered exogenous VOCs to precisely assay metabolic pathways of interest.

Visit website

Owlstone Medical discoveries and awards

2020 2016
  • 2020

    Best Emerging Medtech Company - Winner

    Owlstone Medical won the Best Emerging Medtech Company award at the 2020 OBN Awards. The award was received by Chris Claxton, VP of Investor Relations, at the Royal Lancaster Hotel in London – one of the first in-person events for the life sciences in 2021.

    OBN Awards 2020 – Celebrating Innovation and Achievement in Life Sciences

  • 2019

    ScaleUP of the Year Award - Winner

    The Owlstone Medical team are transforming from an exciting start-up to an established world leader in Breath Biopsy. Evidence of this growth is indicated in the accelerating demand for Breath Biopsy technology integration within clinical trials and research as well as the recent partnership with Renji Hospital in Shanghai.

    29th Annual Business Weekly Awards

  • 2018

    MacRobert Award - Winner Royal Academy of Engineering Award

    Owlstone Medical's ReCIVA Breath Sampler wins the prestigious MacRobert Award. The ReCIVA Breath Sampler, part of the Breath Biopsy® platform, has opened up the potential for earlier diagnosis and precision medicine across cancer, inflammatory disease and infectious disease.

  • 2018

    IPF Catalyst Challenge - Winner

    Owlstone Medical wins the IPF (idiopathic pulmonary fibrosis) Catalyst Challenge - a $333k dollar award to fund research into early detection of IPF using the Breath Biopsy platform.

    Three Lakes Partners

  • 2017

    Business Innovation Award - Winner Cambridge News & Media Business Excellence Awards

    Owlstone Medical wins the Business Innovation Award for its Breath Biopsy® technology in the Cambridge News & Media Business Excellence Awards.

  • 2017

    Royal Academy of Engineering - Silver Medal Winner Royal Academy of Engineering Awards

    Owlstone Medical CEO Billy Boyle is awarded the prestigious Silver Medal in recognition of pioneering work spearheading the development of the company’s Breath Biopsy® platform.

  • 2016

    Life Science Innovation Award - winners Business Weekly

    Owlstone Medical headed off fierce competition to take the AstraZeneca/MedImmune Life Science Innovation Award.

Contact us

Thank you for your enquiry!
We'll be in touch soon.

We couldn't send your message.
Please review the fields then try again